首次递表失效后，圣桐特医再次向港交所递交IPO招股书。根据招股书，2024年，中国特医食品产品的渗透率仅约为3%，远低于欧美等成熟市场的40%，预 计到2029年市场规模将达到531亿元，仍有很大发展空间。圣桐特医背后有着知名乳企圣元国际的加持，不过随着短期偿债压力、研发费用占比过低等因素 凸显，或成为其IPO的关键变量。 知名战略定位专家、福建华策品牌定位咨询创始人詹军豪在接受北京商报记者采访时表示，"存货周转天数大幅上升，总赤字与流动负债净额高，这些财务 状况会让投资者担忧其经营稳定性和抗风险能力，降低投资意愿。在IPO审核中，监管机构也会重点关注企业财务健康状况，若认为其偿债风险过高，可能 影响审核通过，或要求其改善财务状况后再推进IPO进程"。 中国城市专家智库委员会常务副秘书长、浙大城市学院副教授林先平也认为，"短期偿债压力大对其IPO会产生负面影响。港交所审核时会重点关注企业持 续经营能力，而短期偿债压力大正是这一能力的重要隐患。港交所对新申请人需具备足够营业记录且产生净现金流入的核心要求，若无法证明上市后能改善 资金流动性，大概率遭遇估值折价或认购不足"。 短期偿债压力较大 所谓特医食品，全称为 ...

Core Viewpoint - Despite its significant position in niche markets, the company has disclosed concerning signals in its prospectus, including a notable decline in performance in the first half of 2025 and compliance issues [2][4]. Group 1: Company Performance - In 2024, the company ranked second in both the Chinese goat milk powder market and the infant formula goat milk powder market, as well as second among local brands in the infant special medical food market [4]. - The company's revenue from 2022 to 2024 was 1.402 billion, 1.614 billion, and 1.762 billion RMB, with net profits of 227 million, 168 million, and 172 million RMB respectively [9]. - In the first half of 2025, the company reported revenue of 806 million RMB, a year-on-year decline of 10.4%, and a net profit of 56.7 million RMB, down 42.6% year-on-year [11]. Group 2: Business Segments - The company's main business segments include infant formula goat milk powder, special medical food, infant formula cow milk powder, adult and children's milk powder, and OEM and dairy-related materials [6]. - Infant formula goat milk powder and special medical food are the largest contributors, accounting for 58.6% and 12.4% of revenue in 2024, respectively [7]. Group 3: Profitability and Costs - The company's net profit margin has been declining, with rates of 16.2%, 10.4%, 9.8%, and 7.0% from 2022 to the first half of 2025 [15]. - The increase in sales and distribution expenses has contributed to the declining net profit margin, rising from 17.1% of revenue in 2022 to 28.9% in the first half of 2025 [15]. Group 4: Compliance and Governance Issues - The company has faced compliance issues, including failure to fully pay social insurance and housing funds for some employees, and exceeding the legal limit for dispatched workers [17]. - There are concerns regarding the legality of certain properties owned by the company, which were built without proper planning permits, posing risks of penalties or operational disruptions [17]. Group 5: Research and Development - The company has seen a reduction in R&D investment, with expenses of 19.91 million, 8.42 million, and 8.01 million RMB from 2022 to 2024, representing approximately 1.4%, 0.52%, and 0.45% of revenue respectively [26]. - Despite the growth in the special medical food segment, the company faces uncertainties related to industry regulations, market competition, and its operational capabilities [24].